title: Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma.
abstract: BACKGROUND
  Uterine papillary serous carcinoma (UPSC) is an uncommon, aggressive type of endometrial cancer associated with an advanced stage at initial presentation, rapid progression of disease, and poor prognosis.
  
  
  METHODS
  Twenty-three patients with UPSC were included in this study. History, treatment, follow-up, and 5-year overall survival probability (5-yr OS%) were evaluated.
  
  
  RESULTS
  All women underwent total hysterectomy and bilateral salpingo-oophorectomy. Positive lymph nodes were found in 10 of 17 patients who underwent pelvic lymphadenectomy. Eight patients had FIGO Stage I/II, whereas 15 patients showed Stage III or IV tumors. After surgery 5 women underwent radiotherapy, 5 chemotherapy, and 8 both radiotherapy and chemotherapy. Chemotherapy consisted of cisplatin/carboplatin plus cyclophosphamide. Adjuvant irradiation consisted of vault and external beam irradiation. The median duration of follow-up was 39.4 months (25th and 75th percentiles; 26. 1, 68.1). The median overall survival was 43.3 months (12.9, 75th percentile not reached). Three of 10 patients who received only chemotherapy or radiotherapy are alive, whereas 7/8 patients who received a combination of both are alive with no evidence of disease at the time of reporting. The 5-yr OS% was 80% in those who received radio- and chemotherapy and only 30% in those who were treated with radiotherapy alone (log rank = 0.05).
  
  
  CONCLUSIONS
  These results stress the need to study and evaluate the usefulness of combined chemo- and radiation therapy in patients with uterine serous papillary cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Department of Pathology, Gynecopathological Unit, University Hospital of Vienna, Währinger G urtel 18-20, Vienna, A-1090, Austria.
authors.forename: D
authors.initials: D
authors.lastname: Bancher-Todesca
authors.forename: W
authors.initials: W
authors.lastname: Neunteufel
authors.forename: K E
authors.initials: KE
authors.lastname: Williams
authors.forename: D
authors.initials: D
authors.lastname: Prainsack
authors.forename: G
authors.initials: G
authors.lastname: Breitenecker
authors.forename: M L
authors.initials: ML
authors.lastname: Friedlander
authors.forename: N F
authors.initials: NF
authors.lastname: Hacker
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D018283:Cystadenocarcinoma, Papillary / Q000401:mortality* / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D011182:Postoperative Care; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000401:mortality* / Q000628:therapy*